200 related articles for article (PubMed ID: 28991933)
21. Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
Geurin MD
Am Fam Physician; 2016 Mar; 93(6):436-8. PubMed ID: 26977827
[No Abstract] [Full Text] [Related]
22. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
Packer M
Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
[No Abstract] [Full Text] [Related]
23. [Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)].
Scheen AJ; Mathieu C
Rev Med Liege; 2018 Oct; 73(10):526-532. PubMed ID: 30335259
[TBL] [Abstract][Full Text] [Related]
24. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
Kalra S; Gupta Y
J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
[TBL] [Abstract][Full Text] [Related]
25. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
Athyros VG; Katsiki N; Tentolouris N
Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
[No Abstract] [Full Text] [Related]
26. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Basal insulins.
Mora PF
J Fam Pract; 2017 Oct; 66(10 Suppl):S7-S11. PubMed ID: 28991931
[TBL] [Abstract][Full Text] [Related]
27. Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.
Med Lett Drugs Ther; 2017 Sep; 59(1529):147-149. PubMed ID: 28880845
[No Abstract] [Full Text] [Related]
28. [Insulinization in type 2 diabetes mellitus. Intensification options].
Fuente GV; Sinay I; Costa Gil JE; Puchulu F; Dieuzeide G; Rodríguez M; Faingold MC; Litwak LE
Medicina (B Aires); 2016; 76(3):173-9. PubMed ID: 27295707
[TBL] [Abstract][Full Text] [Related]
29. Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.
Terakawa A; Chujo D; Yasuda K; Ueno K; Nakamura T; Hamano S; Ohsugi M; Tanabe A; Ueki K; Kajio H
Medicine (Baltimore); 2020 Aug; 99(35):e21939. PubMed ID: 32871938
[TBL] [Abstract][Full Text] [Related]
30. Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes.
Gomez-Peralta F; Al-Ozairi E; Jude EB; Li X; Rosenstock J
Diabetes Obes Metab; 2021 Jul; 23(7):1445-1452. PubMed ID: 33651460
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
32. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
Iepsen EW; Torekov SS; Holst JJ
Expert Rev Cardiovasc Ther; 2015; 13(7):753-67. PubMed ID: 26106933
[TBL] [Abstract][Full Text] [Related]
33. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
George C; Byun A; Howard-Thompson A
Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
[TBL] [Abstract][Full Text] [Related]
34. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
35. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
Darmon P; Raccah D
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
[TBL] [Abstract][Full Text] [Related]
36. Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice.
Artigas CF; Stokes V; Tan GD; Theodorakis MJ
Expert Opin Pharmacother; 2015; 16(10):1417-21. PubMed ID: 26077113
[TBL] [Abstract][Full Text] [Related]
37. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
Shaefer CF; Anderson J
Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
[TBL] [Abstract][Full Text] [Related]
38. Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?
Maiza JC; Gérard P; Rollot O; Cogne M; Jarlet E; Schneebeli S
Minerva Endocrinol; 2016 Mar; 41(1):138-40. PubMed ID: 26878563
[No Abstract] [Full Text] [Related]
39. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
[TBL] [Abstract][Full Text] [Related]
40. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
